MX2023005707A - Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina. - Google Patents

Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina.

Info

Publication number
MX2023005707A
MX2023005707A MX2023005707A MX2023005707A MX2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A MX 2023005707 A MX2023005707 A MX 2023005707A
Authority
MX
Mexico
Prior art keywords
glp
agonists
compound
amylin receptors
pharmaceutical formulation
Prior art date
Application number
MX2023005707A
Other languages
English (en)
Spanish (es)
Inventor
Christian Wenzel Tornøe
Thomas Kruse
Østergaard Søren
Anne Louise Bank Kodal
Wouter Frederik Johan Hogendorf
Johnny Madsen
Schäffer, (Fallecido) Lauge
Alice Ravn Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2023005707A publication Critical patent/MX2023005707A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023005707A 2020-12-18 2021-12-17 Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina. MX2023005707A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20215291 2020-12-18
EP21154668 2021-02-02
EP21179810 2021-06-16
PCT/EP2021/086494 WO2022129526A1 (en) 2020-12-18 2021-12-17 Co-agonists of the glp-1 and amylin receptors

Publications (1)

Publication Number Publication Date
MX2023005707A true MX2023005707A (es) 2023-07-31

Family

ID=79024591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023005707A MX2023005707A (es) 2020-12-18 2021-12-17 Coagonistas de los receptores de péptido-1 similar a glucagón humano (glp-1) y amilina.
MX2025000872A MX2025000872A (es) 2020-12-18 2023-05-16 Coagonistas de los receptores de peptido-1 similar a glucagon humano (glp-1) y amilina

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025000872A MX2025000872A (es) 2020-12-18 2023-05-16 Coagonistas de los receptores de peptido-1 similar a glucagon humano (glp-1) y amilina

Country Status (15)

Country Link
US (3) US12054528B2 (enExample)
EP (1) EP4263581A1 (enExample)
JP (1) JP7554928B2 (enExample)
KR (3) KR102667196B1 (enExample)
CN (4) CN121975020A (enExample)
AU (2) AU2021403851B2 (enExample)
CA (1) CA3201088A1 (enExample)
CL (1) CL2023001714A1 (enExample)
CO (1) CO2023008866A2 (enExample)
IL (2) IL303127A (enExample)
MX (2) MX2023005707A (enExample)
MY (1) MY209195A (enExample)
PE (1) PE20231659A1 (enExample)
TW (3) TW202620039A (enExample)
WO (1) WO2022129526A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AR127945A1 (es) 2021-12-13 2024-03-13 Novo Nordisk As Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
CN118973602A (zh) 2022-03-30 2024-11-15 诺和诺德股份有限公司 配制方法
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
CN119654159A (zh) * 2022-08-05 2025-03-18 印第安纳大学研究与技术公司 胰高血糖素样肽-1受体拮抗剂
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
AU2024305247A1 (en) 2023-06-15 2025-12-11 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
TWI926512B (zh) * 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
TWI913094B (zh) * 2024-01-29 2026-01-21 免疫功坊股份有限公司 適合舌下給藥的類升糖素肽-1受體促效劑肽的藥學配方
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721760A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721761A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US20260091086A1 (en) * 2024-05-20 2026-04-02 Medimmune Limited Polypeptide combinations and uses thereof
WO2025264979A1 (en) * 2024-06-21 2025-12-26 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof
WO2026008836A1 (en) * 2024-07-05 2026-01-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2026013265A1 (en) 2024-07-12 2026-01-15 Novo Nordisk A/S Novel dipeptide acylating agents
WO2026067799A1 (zh) * 2024-09-30 2026-04-02 杭州先为达生物科技股份有限公司 Glp-1受体和胰淀素受体的共激动剂
KR102991397B1 (ko) * 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도
WO2026124639A1 (zh) * 2024-12-12 2026-06-18 深圳信立泰药业股份有限公司 多重受体共激动剂及其制备方法与应用
CN120305390B (zh) * 2025-06-18 2025-10-03 杭州思诺达医药科技有限责任公司 一种降血糖的药物制剂

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501942A (ja) 1992-09-30 1996-03-05 ザイモジェネティクス，インコーポレイティド ヒト カルシトニン レセプター
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR20140011431A (ko) * 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
JP2013511287A (ja) * 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
US20120329711A1 (en) * 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) * 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
EP2718315B1 (en) 2011-06-10 2017-12-27 Novo Nordisk A/S Pramlintide derivatives
MX354705B (es) * 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2014283221A1 (en) 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
AR103954A1 (es) * 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
CN105367664B (zh) * 2015-11-04 2019-09-20 成都贝爱特生物科技有限公司 激活GLP-1受体和Amylin受体双功能作用的融合蛋白制备及其用途
BR102015031283A2 (pt) 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
CN108424460A (zh) 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物

Also Published As

Publication number Publication date
IL325793A (en) 2026-03-01
CN121975020A (zh) 2026-05-05
CN121991202A (zh) 2026-05-08
PE20231659A1 (es) 2023-10-17
AU2021403851A9 (en) 2025-03-20
EP4263581A1 (en) 2023-10-25
IL303127A (en) 2023-07-01
US12054528B2 (en) 2024-08-06
US20240279299A1 (en) 2024-08-22
TW202620039A (zh) 2026-05-16
TW202227474A (zh) 2022-07-16
CL2023001714A1 (es) 2024-01-05
AU2021403851B2 (en) 2025-09-25
TW202440619A (zh) 2024-10-16
TW202615455A (zh) 2026-04-16
MY209195A (en) 2025-06-26
CO2023008866A2 (es) 2023-10-09
KR20240074867A (ko) 2024-05-28
MX2025000872A (es) 2025-03-07
WO2022129526A1 (en) 2022-06-23
CN121991249A (zh) 2026-05-08
JP2023553591A (ja) 2023-12-25
CN116669753A (zh) 2023-08-29
AU2025248685A1 (en) 2025-10-30
KR20250165665A (ko) 2025-11-26
JP7554928B2 (ja) 2024-09-20
KR20230019499A (ko) 2023-02-08
US20260132182A1 (en) 2026-05-14
TWI850611B (zh) 2024-08-01
KR102667196B1 (ko) 2024-05-27
AU2021403851A1 (en) 2023-06-15
CA3201088A1 (en) 2022-06-23
KR102884383B1 (ko) 2025-11-14
US20230331803A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
MX2025000872A (es) Coagonistas de los receptores de peptido-1 similar a glucagon humano (glp-1) y amilina
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
MX2022009523A (es) Formulaciones farmaceuticas.
CL2024001588A1 (es) Formulaciones farmacéuticas que comprenden una ciclodextrina
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
DE602006003432D1 (de) Latoren des androgenrezeptors
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
MX2010006388A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina.
MX2014012408A (es) Formulacion farmaceutica disponible por via oral adecuada para manejo mejorado de trastornos del movimiento.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
UA122873C2 (uk) Контрацептивний засіб на основі дроспіренону для пацієнтки, що страждає від надлишкової маси тіла
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
ZA202107826B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4321213A3 (en) Oral octreotide administered in combination with other therapeutic agents
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
AR132977A1 (es) Formulaciones farmacéuticas que comprenden una ciclodextrina
WO2011011847A8 (en) Pharmaceutical composition for treating medical conditions and a method for treating alimentary disorders and related diseases
AR131469A1 (es) Agonistas del receptor de amilina
CO2025008319A2 (es) Agonistas del receptor de amilina
PH12021553215A1 (en) Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
Singh Urticaria: case report
Mehta Headaches: case report